Sarah Hogan advises companies in the life sciences and digital health industries in connection with structuring and negotiating intellectual property licenses, strategic collaborations and other complex commercial transactions. Drawing on her scientific background and private practice experience, she delivers practical solutions that lay the groundwork for successful, productive collaborations.

Ms. Hogan has counseled a range of clients in the life sciences, healthcare and technology industries, including startups, venture capital and private equity–backed entities, privately held businesses, hospitals, nonprofit research organizations, and large public companies. She has experience advising on complex matters that include license and collaboration transactions to develop and commercialize pharmaceutical products; cross-industry collaborations, joint development arrangements and joint ventures to develop and deliver products at the intersection of health, technology and life sciences; licensing patents, software and other technology from universities; licensing of data products and data analytics solutions involving health information; licensing of health IT products for both on-premise and hosted (including cloud-based) solutions; and manufacturing, supply and distribution agreements relating to pharmaceutical products at all stages of the product lifecycle. 


  • Ms. Hogan has represented: 

    • Seaport Therapeutics, a clinical-stage biopharmaceutical dedicated to advancing novel neuropsychiatric medicines, in its spin-off from PureTech Health and $100 Million Series A financing round.
    • Verve Therapeutics in a research collaboration with Eli Lilly and Company focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
    • Voyager Therapeutics, a biotechnology company dedicated to advancing neurogenetic medicines, in its strategic collaboration agreement with Neurocrine Biosciences to advance multiple gene therapies for the treatment of neurological diseases; and its strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
    • Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics, in a strategic collaboration with Swedish Orphan Biovitrum AB (Sobi) valued at up to $1.25 billion to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need.
    • Arbor Biotechnologies, an early-stage life sciences company focused on genetic medicines, in its strategic partnership with 4D Molecular Therapeutics focused on treating large market diseases; strategic research collaboration agreement with Vertex Pharmaceutical valued at up to $1.2 billion; strategic research collaboration with TCR2 Therapeutics focused on the development of allogeneic TRuC-T cell therapies; and worldwide non-exclusive license agreement with EdiGene to advance Ex Vivo engineered cell therapy programs.
    • Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, in its multi-target research collaboration with Pfizer valued at up to $1.35 billion.
    • Benu Networks, a leading software and solutions provider, in its acquisition by Ciena Corporation.
    • Charles River Laboratories in a multiyear strategic partnership with Valo Health to offer a transformative, artificial intelligence (AI)-enabled drug discovery and development platform.
    • Nuance Communications in its strategic partnership with Microsoft aimed at accelerating the delivery of ambient clinical intelligence (ACI) technologies to reduce clinician burnout.
    • Transgene SA, a French biotech company focused on developing virus-based immunotherapies for cancer and infectious diseases, in its strategic collaboration with AstraZeneca to develop innovative oncolytic virus immunotherapies.
    • Voyager Therapeutics, a gene therapy company developing treatments for next-generation adeno-associated virus capsids, in its license option agreement with Novartis to develop first-in-class gene therapies for neurological disorders, and its licensing agreement with Pfizer focused on the development of TRACER AAV capsids.


  • Selected by peers for inclusion in the 2020–2024 editions of the Best Lawyers in America in the area of healthcare law. 
  • Consistently recognized as a "Life Sciences Star" by LMG Life Sciences from 2016 to 2023.
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021, 2022 and 2023 in the area of corporate law.

Insights & News


  • Education

    • JD, Northeastern University School of Law, 2005

    • MS, Genetics, University of New Hampshire, 1999

    • BS, Biotechnology, Worcester Polytechnic Institute, 1996

  • Admissions

    • Massachusetts



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.